Jolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the transaction, the senior vice president now directly owns 2,926 shares in the company, valued at $125,291.32. This trade represents a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Down 0.1 %

Mirum Pharmaceuticals stock traded down $0.06 during mid-day trading on Wednesday, reaching $42.00. The stock had a trading volume of 305,985 shares, compared to its average volume of 405,737. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -20.79 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a 50-day moving average price of $42.80 and a two-hundred day moving average price of $40.60. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same period last year, the business posted ($0.57) EPS. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners upped their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $57.10.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares during the last quarter. Amalgamated Bank increased its position in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares during the last quarter. Arizona State Retirement System lifted its holdings in Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock valued at $315,000 after acquiring an additional 883 shares during the period. Quest Partners LLC increased its position in shares of Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Mirum Pharmaceuticals by 17.1% in the 2nd quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company’s stock worth $480,000 after purchasing an additional 2,050 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.